These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39251589)

  • 1. Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study.
    Daniilidou M; Holleman J; Hagman G; Kåreholt I; Aspö M; Brinkmalm A; Zetterberg H; Blennow K; Solomon A; Kivipelto M; Sindi S; Matton A
    Transl Psychiatry; 2024 Sep; 14(1):364. PubMed ID: 39251589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Janelidze S; Mattsson N; Stomrud E; Lindberg O; Palmqvist S; Zetterberg H; Blennow K; Hansson O
    Neurology; 2018 Aug; 91(9):e867-e877. PubMed ID: 30054439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD; Chambers AB; Ott BR; Daiello LA;
    J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diurnal cortisol, neuroinflammation, and neuroimaging visual rating scales in memory clinic patients.
    Holleman J; Daniilidou M; Kåreholt I; Aspö M; Hagman G; Udeh-Momoh CT; Spulber G; Kivipelto M; Solomon A; Matton A; Sindi S
    Brain Behav Immun; 2024 May; 118():499-509. PubMed ID: 38503394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating small extracellular vesicles in Alzheimer's disease: a case-control study of neuro-inflammation and synaptic dysfunction.
    Singh R; Rai S; Bharti PS; Zehra S; Gorai PK; Modi GP; Rani N; Dev K; Inampudi KK; Y VV; Chatterjee P; Nikolajeff F; Kumar S
    BMC Med; 2024 Jun; 22(1):254. PubMed ID: 38902659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
    Gertje EC; Janelidze S; van Westen D; Cullen N; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N
    Neurology; 2023 Apr; 100(17):e1812-e1824. PubMed ID: 36882326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive reserve, cortisol, and Alzheimer's disease biomarkers: A memory clinic study.
    Yerramalla MS; Darin-Mattsson A; Udeh-Momoh CT; Holleman J; Kåreholt I; Aspö M; Hagman G; Kivipelto M; Solomon A; Marseglia A; Sindi S
    Alzheimers Dement; 2024 Jul; 20(7):4486-4498. PubMed ID: 38837661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate.
    Ouanes S; Rabl M; Clark C; Kirschbaum C; Popp J
    Alzheimers Res Ther; 2022 Dec; 14(1):190. PubMed ID: 36529757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.
    Wang LY; Raskind MA; Wilkinson CW; Shofer JB; Sikkema C; Szot P; Quinn JF; Galasko DR; Peskind ER
    Int J Geriatr Psychiatry; 2018 May; 33(5):763-768. PubMed ID: 29446123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Neuroinflammation and Amyloid PET Markers in Predicting Disease Progression in Cognitively Impaired Subjects.
    Leng F; Hinz R; Gentleman S; Dani M; Brooks DJ; Edison P
    J Alzheimers Dis; 2024; 100(3):973-986. PubMed ID: 39031352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.
    Brosseron F; Maass A; Kleineidam L; Ravichandran KA; Kolbe CC; Wolfsgruber S; Santarelli F; Häsler LM; McManus R; Ising C; Röske S; Peters O; Cosma NC; Schneider LS; Wang X; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Buerger K; Janowitz D; Dichgans M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Görß D; Laske C; Munk MH; Düzel E; Yakupow R; Dobisch L; Metzger CD; Glanz W; Ewers M; Dechent P; Haynes JD; Scheffler K; Roy N; Rostamzadeh A; Spottke A; Ramirez A; Mengel D; Synofzik M; Jucker M; Latz E; Jessen F; Wagner M; Heneka MT;
    Alzheimers Res Ther; 2023 Jan; 15(1):13. PubMed ID: 36631909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol, cognition and Alzheimer's disease biomarkers among memory clinic patients.
    Holleman J; Adagunodo S; Kåreholt I; Hagman G; Aspö M; Udeh-Momoh CT; Solomon A; Kivipelto M; Sindi S
    BMJ Neurol Open; 2022; 4(2):e000344. PubMed ID: 36277478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.